Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent)

Medical Services Advisory Committee
Record ID 32015000435
English
Authors' recommendations: After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of ALK gene rearrangement testing to select eligible patients with NSCLC for crizotinib treatment, MSAC deferred finalising its advice to the Minister on public funding until PBAC makes a positive recommendation regarding crizotinib and the issues raised by MSAC above regarding the testing have been addressed. These include: further information on how ALK testing (both IHC and FISH) should be incorporated into the overall test strategy in NSCLC to: - make best use of small volume tumour specimens - optimise high-level pathology expertise required - minimise unnecessary testing - optimally integrate with EGFR mutation testing - maximise the clinical validity and utility of the testing algorithm. MSAC foreshadowed that the MBS item descriptor should then align with the PBS restriction.
Details
Project Status: Completed
Year Published: 2013
URL for published report: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1250-public
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Australia
MeSH Terms
  • Anaplastic Lymphoma Kinase
  • Crizotinib
  • Carcinoma, Non-Small-Cell Lung
  • Protein Kinase Inhibitors
  • Lung Neoplasms
  • In Situ Hybridization, Fluorescence
Contact
Organisation Name: Medical Services Advisory Committee
Contact Address: MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name: msac.secretariat@health.gov.au
Contact Email: msac.secretariat@health.gov.au
Copyright: <p>Medical Services Advisory Committee (MSAC)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.